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(Author list continued on next page)SummaryFamilial, sequencing, and genome-wide association studies (GWASs) and genetic correlation analyses have progressively unraveled
the shared or pleiotropic germline genetics of breast and ovarian cancer. In this study, we aimed to leverage this shared germline
genetics to improve the power of transcriptome-wide association studies (TWASs) to identify candidate breast cancer and ovarian
cancer susceptibility genes. We built gene expression prediction models using the PrediXcan method in 681 breast and 295 ovarian
tumors from The Cancer Genome Atlas and 211 breast and 99 ovarian normal tissue samples from the Genotype-Tissue Expression
project and integrated these with GWAS meta-analysis data from the Breast Cancer Association Consortium (122,977 cases/105,974
controls) and the Ovarian Cancer Association Consortium (22,406 cases/40,941 controls). The integration was achieved through
application of a pleiotropy-guided conditional/conjunction false discovery rate (FDR) approach in the setting of a TWASs. This iden-
tified 14 candidate breast cancer susceptibility genes spanning 11 genomic regions and 8 candidate ovarian cancer susceptibility
genes spanning 5 genomic regions at conjunction FDR < 0.05 that were >1 Mb away from known breast and/or ovarian cancer sus-
ceptibility loci. We also identified 38 candidate breast cancer susceptibility genes and 17 candidate ovarian cancer susceptibility
genes at conjunction FDR < 0.05 at known breast and/or ovarian susceptibility loci. The 22 genes identified by our cross-cancer anal-
ysis represent promising candidates that further elucidate the role of the transcriptome in mediating germline breast and ovarian
cancer risk.Introduction
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Transcriptome-wide association studies (TWASs) repre-
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ease-associated susceptibility genes. TWASs involve estab-
lishing robust multi-variant models for the component
of somatic (normal or tumor) gene expression that is regu-
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expression. Moving from single variants (GWASs) to genes
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variants that predominantly reside in non-coding regions
of the genome.7
PrediXcan is a method developed recently for con-
ducting TWASs.8 TWAS methods have been applied to sin-
gle cancer types before, including breast cancer9,10 and
ovarian cancer.11,12 Here we present an application of Pre-
diXcan, and indeed broadly of TWASs, in the pleiotropic
cross-cancer setting.We used the normal and tumor breast-
and ovary-specific gene expression and matched germline
genotype datasets to generate tissue-specific PrediXcan
models and first imputed these models into GWAS data
for the corresponding cancers (i.e., from breast-tissue-
derived models into breast cancer GWASs and likewise
for the ovarian models). We then imputed models across
cancer types (i.e., from breast-tissue-derived models into
ovarian cancer GWASs and vice versa). Finally, we imple-
mented a powerful conjunction false discovery rate (FDR)
approach13,14 that has been applied previously to
GWASs,15–18 but not to TWASs, to leverage the combined
GWAS sample of over 145,000 breast and ovarian cancer
cases. We identify candidate breast and ovarian cancer sus-
ceptibility genes in regions not previously implicated by
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Material and methods
Matched germline genotype: normal/tumor gene
expression datasets
We used data for 211 normal breast tissue samples and 99 normal
ovarian tissue samples from the Genotype-Tissue Expression
(GTEx) project (version 7 release).19 Germline genotypes in the
GTEx data had been called from whole-genome sequencing (Illu-
mina HiSeq X), and gene expression was profiled using RNA-
sequencing (Illumina TruSeq). We also used data from 681 breast
cancer20 and 295 high-grade serous ovarian cancer (HGSOC)21
cases from The Cancer Genome Atlas (TCGA) network. Germline
genotypes in the TCGA data had been called from genotyping ar-
rays (Affymetrix SNP 6.0), and gene expression was profiled using
RNA-sequencing (Illumina HiSeq 2000). Imputation of TCGA
germline genotypes using the 1000 Genomes version 5 reference
panel was performed as described previously.22,23 TCGA sample
sizes reported here refer to only those samples that had >95% Eu-
ropean ancestry. Ancestry was estimated using the Local Ancestry
in adMixed Populations tool (LAMP version 2.5).24 Downstream
PrediXcan modeling (described below) used variants imputed
with quality > 0.8 that had a minor allele frequency > 5% in
TCGA datasets.
Genome-wide association datasets
Summary statistics from genome-wide association meta-analyses
were obtained from the Breast Cancer Association Consortium
(BCAC)22 and the Ovarian Cancer Association Consortium
(OCAC).23 The breast cancer susceptibility data were based on
122,977 cases and 105,974 controls, including 21,468 estrogen re-
ceptor (ER)-negative cases. The ovarian cancer susceptibility data
were based on 22,406 epithelial ovarian cancer cases and 40,941
controls, including 13,037 HGSOC cases. We harmonized the
signs of the effect size estimates and aligned them to the same ef-
fect allele in the breast and ovarian cancer GWAS datasets. We re-
tained 9,530,997 variants with minor allele frequency > 1% and
imputation quality > 0.4 in both datasets for S-PrediXcan ana-
lyses. All individuals in these studies were of genetically inferred
European ancestry.
PrediXcan model development and S-PrediXcan
analyses
We built genetically regulated gene expression prediction models
using the elastic net regularization approach implemented in Pre-
diXcan and validated these models using tenfold cross-valida-
tion.8 Essentially, this generates a list of variants for each gene
where model construction is successful and each variant in the
list is assigned a weight reflecting its influence on its target gene
expression. Genes with models where the nested tenfold cross-
validated correlation between predicted and actual levels of
expression was >10% (predictive performance r2 > 0.01) and p
value of the correlation test was <0.05 were retained. These
models were adjusted for the latent determinants of gene expres-
sion variation (referred to hereafter as PEER factors), which were
identified using the Probabilistic Estimation of Expression Resid-
uals (PEER; version 1.3) method.25 We adjusted for 60 and 45
PEER factors for TCGA breast and ovarian cancer data, respec-
tively. The choice of these numbers is a function of sample size
and consistent with recommendations.8,25 ESR1 expression was
also included as a covariate in the construction of breast cancer
models to account for ER status and its influence on the expressionH
of individual genes. For the GTEx version 7 datasets, we down-
loaded pre-computed PrediXcan models from predictdb.org. Our
pipeline for processing the TCGA datasets, including the applica-
tion of PEER factors, was designed to be consistent with the pipe-
line used to generate the pre-computed GTEx PrediXcan models.
S-PrediXcan refers to the application of the PrediXcan gene expres-
sion models, specifically the variant weights from elastic net
combined into multi-variant gene-level instruments, to summary
statistics GWAS datasets and has been described in detail before.8
The variance of a gene’s expression that was explained by the
SNPs in its model was calculated as W0 3 G 3 W (where W is
the vector of SNP weights in a gene’s model, W0 is its transpose,
and G is the covariance matrix).Conditional and conjunction FDR analyses
We obtained p values for association of predicted expression of
each gene with breast cancer risk and with ovarian cancer risk.
We then computed the FDR for gene-breast cancer risk association
conditional on gene-ovarian cancer risk association (as condi-
tional FDRBreast CancerjOvarian Cancer). This is the probability that a
gene is not associated with breast cancer risk given the p values
for association with both breast cancer risk and ovarian cancer
risk. The analogous conditional FDR for gene-ovarian cancer risk
association was also calculated (FDROvarian CancerjBreast Cancer).
Finally, the conjunctional FDR estimate, which is conservatively
defined as the maximum of the two conditional FDR values, was
computed. This processminimizes the effect of a single phenotype
(in this case, breast or ovarian cancer) driving the shared associa-
tion signal. It allows the power of pleiotropic associations to be
tapped for genetic discovery, unlike a traditional FDR approach
that is informed solely by the distribution of p values for a single
phenotype. We used the R implementation of the conditional
FDR method. The conditional and conjunctional FDR method
has been described extensively elsewhere13–18 but not applied
before to the TWAS setting. The overall study design is summa-
rized in Figure 1.Fine-mapped candidate causal risk variant datasets
We examined the overlap between variants in the breast gene
expression prediction models and a published list of fine-mapped
candidate causal risk variants for breast cancer.26 This was done to
follow up genes that we identified in genomic regions that are
known to be associated with breast cancer risk under the intuition
that gene-level association signals identified by S-PrediXcan that
demonstrate such overlap with fine-mapped variants are likely be-
ing driven by the GWAS association signal in the same region.
Fine-mapped candidate causal risk variants lists for breast cancer
were obtained from Fachal et al.26 Briefly, Fachal et al. fine-mapped
150 known breast cancer susceptibility regions using dense geno-
type data on women participating in the BCAC and in the
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Stepwise multinomial logistic regression was used to identify inde-
pendent association signals in each region. Credible causal vari-
ants within each signal were defined as being within a 100-fold
likelihood of the top conditional variant to delineate the variants
driving the GWAS associations in each region.
We adopted a similar analytic strategy for the ovarian cancer da-
taset fromOCAC. Each genomic regionwith a genome-wide signif-
icant (p < 5 3 108) variant was explored to identify additional
independent association signals. All variants within a given
genomic regionwere jointly analyzed to evaluate the simultaneousuman Genetics and Genomics Advances 2, 100042, July 8, 2021 3
Figure 1. Overview of datasets and analyses in this study
Flowchart providing an overview of the datasets used and the various steps in the analysis. GTEx, Genotype-Tissue Expression project;
TCGA, The Cancer Genome Atlas; GWAS, genome-wide association study; FDR, false discovery rate.effects of multiple variants, using a 1 Mb window centered on the
most significant variant, in stepwise conditional models. Given
the presence of a genome-wide significant variant in the region,
the prior probability of an additional risk variant in the same region
is higher than in a region without a genome-wide significant lead
variant; therefore, we used a threshold of p < 1 3 105 to identify
additional independent association signals. All variants in each re-
gionwere ranked by the likelihood of associationwith ovarian can-
cer based on p values. The likelihood of each variant was then
comparedwith the likelihoodof the leadvariant in the regionbased
on theprimary association analysis for primary signals and the con-
ditional association analysis for conditional signals. Variants with
odds > 1:100 compared with the lead variant (corresponding to a
p value 100 times larger than the most significant p value27) were
selected as credible causal variants.Results
Development of tissue/tumor-specific gene expression
prediction models
We built genetically regulated gene expression predictor
models using matched germline genotype and tumor
gene expression data from TCGA by applying elastic net
regularization as implemented in the PrediXcan software.
Genes with models where the nested tenfold cross-vali-
dated correlation between predicted and actual levels of
expression was >10% (predictive performance r2 > 0.01)
and p value of the correlation test was <0.05 were retained
in line with best practice quality control recommendations
by the developers of PrediXcan.8 We constructed and eval-4 Human Genetics and Genomics Advances 2, 100042, July 8, 2021uated predictor models that met these criteria for 4,457
genes based on 681 TCGA breast tumor samples and for
2,705 genes based on 295 TCGA ovarian tumor samples.
We obtained pre-computed genetically regulated gene
expression predictor models that met the same criteria
(predictive performance r2 > 0.01; correlation test p <
0.05) in matched germline genotype and normal tissue
gene expression data from the GTEx Project. Specifically,
the pre-computed data included 5,274 genes modeled
based on 211 GTEx breast tissue samples and 3,034 genes
modeled based on 99 GTEx ovarian tissue samples. The
variance of a gene’s expression explained by SNPs in its
model was, on average, lower in tumors and higher in
normal tissues (mean [standard deviation] for TCGA breast
cancer: 0.04 [0.07]; TCGA ovarian cancer: 0.05 [0.06)];
GTEx breast: 0.09 [0.09]; and GTEx ovary: 0.15 [0.13]),
likely reflecting the relatively smaller influence of germline
genetic variation on tumor gene expression compared to
its impact on normal tissue gene expression. Prediction
performance as measured by the cross-validated correla-
tion of the tissue model’s correlation to the gene’s
measured transcriptome was, in general, substantially bet-
ter for the normal tissue models than the tumor tissue
models (Figure S1).
Imputation of gene expression into GWAS and
pleiotropy-guided FDR control
We used the GTEx normal breast-tissue-derived prediction
models to impute genetically regulated gene expression in
a genome-wide association meta-analysis involving
122,977 breast cancer cases and 105,974 controls using
S-PrediXcan. We tested for association between imputed
gene expression and breast cancer risk. We also used the
same GTEx breast-tissue-based models to impute gene
expression in a genome-wide association meta-analysis
of 22,406 ovarian cancer cases and 40,941 controls and
test for association between imputed expression and
ovarian cancer risk. For these two steps, we applied the
conditional FDR method to the S-PrediXcan gene-level as-
sociation p values to correct for testing 5,274 genes in
each analysis. This yielded two conditional FDR values:
one for association with breast cancer risk given associa-
tion with ovarian cancer risk and the other for association
with ovarian cancer risk given association with breast can-
cer risk. Finally, we took the larger of the two values for
each gene as a conservative estimate of its conjunction
FDR to identify candidate breast cancer susceptibility
genes at conjunction FDR < 0.05. We refer to these genes
as candidate breast cancer susceptibility genes because
they were identified on the basis of gene expression pre-
dictor models derived from breast tissue. However, the
conditional-conjunction FDR analysis effectively bor-
rowed information from pleiotropic associations with in-
herited susceptibility to a second cancer type (in this
case ovarian cancer) in addition to the primary cancer
type (breast cancer), and these genes may be considered
as risk genes for the second cancer as well. These steps
were repeated for three other ordered combinations of da-
tasets: TCGA breast tumor tissue-breast cancer GWAS-
ovarian cancer GWAS to identify candidate breast cancer
susceptibility genes; GTEx normal ovarian tissue-ovarian
cancer GWAS-breast cancer GWAS and TCGA ovarian tu-
mor tissue-ovarian cancer GWAS-breast cancer GWAS to
identify candidate ovarian cancer susceptibility genes.
We also replaced the overall breast cancer GWASs and all
invasive ovarian cancer GWASs used in the four dataset
combinations described above with ER-negative breast
cancer GWASs (21,468 cases/105,974 controls) and
HGSOC GWASs (13,037 cases/22,406 controls), respec-
tively. This helped identify additional candidate breast
and ovarian cancer susceptibility genes driven by sub-
type-specific associations at conjunction FDR < 0.05.
For each gene, coverage was defined as the percentage of
the number of variants included in its expression predic-
tion model that were also captured in the genome-wide as-
sociation meta-analysis. The coverage was R80% for at
least 93% of the genes in each of the four matched germ-
line genotype and normal or tumor gene expression data-
sets used to build the predictor models, indicating that for
most genes, most of the corresponding model variants
available were used. In each ordered analytic combination
of datasets (e.g., GTEx normal breast tissue-breast cancer
GWAS-ovarian cancer GWAS) we observed that, in general,
for progressively smaller S-PrediXcan p values of the sec-
ond cancer type, the true discovery rate for association
with the primary cancer type approached 100% at progres-H
sively larger S-PrediXcan p values for the primary cancer
type (Figure 2; Figure S2). This was consistent with substan-
tial shared gene-level associations for breast and ovarian
cancer risk and these shared signals being tapped by the
conditional-conjunction FDR method to power candidate
susceptibility gene discovery.
Identification of candidate breast cancer and ovarian
cancer susceptibility genes
We identified 14 candidate breast cancer susceptibility
genes at the conjunction FDR< 0.05 threshold (Table 1; Ta-
ble S1). The 14 genes were distributed between 11 genomic
regions>1Mb apart from each other (Table 1). These genes
have not been reported as susceptibility genes in any prior
TWAS of breast cancer risk and are >1 Mb away from pub-
lished genome-wide significant lead variants for breast can-
cer susceptibility.28 For ovarian cancer, we identified 8
candidate susceptibility genes at conjunction FDR < 0.05
(Table 2; Table S2). The 8 genes were located across 5
genomic regions >1 Mb apart from each other (Table 2).
These genes have not been reported as candidate risk genes
in anypreviously reportedTWASsof ovarian cancer risk and
are >1 Mb away from published genome-wide significant
lead variants for ovarian cancer susceptibility.23
Candidate breast cancer and ovarian cancer
susceptibility genes at known GWAS loci
We identified 38 candidate breast cancer susceptibility
genes that were located within 1 Mb of a published lead
variant associated at genome-wide significance with breast
cancer risk (Table S3).28 Four of the 38 genes have also been
reported in previously published TWASs (Table S3).9,10 The
38 genes were spread across 12 genomic regions >1 Mb
apart from each other. Overlaying fine-mapped candidate
causal breast cancer risk variants on breast gene expression
predictor model variants showed that for 21/38 (55%)
genes, the prediction model variants included at least
one fine-mapped candidate causal variant (Tables S3 and
S4). This suggested that, for these genes, the GWAS associ-
ation signal was driving the S-PrediXcan signal. We also
identified three additional genes that were >1 Mb away
from knownGWAS loci that have previously been reported
as TWAS loci for breast cancer risk (Table S3).9,10
For ovarian cancer, we identified 17 candidate suscepti-
bility genes that were located within 1 Mb of a published
lead variant associated at genome-wide significance with
ovarian cancer risk (Table S5).23 Six of these genes have
also been reported in a previously published TWAS for
ovarian cancer (Table S5).11,12 The 17 genes span 5
different genomic regions >1 Mb apart. Overlaying fine-
mapped candidate causal ovarian cancer risk variants
onto the ovarian gene expression predictor model variants
showed that for 12/17 (71%) genes, the prediction model
variants included at least one fine-mapped candidate
causal variant (Tables S5 and S6), suggesting that for these
genes the GWAS association signal underpinned the S-Pre-
diXcan signal.uman Genetics and Genomics Advances 2, 100042, July 8, 2021 5
Figure 2. True discovery rate of S-PrediXcan associations for each cancer stratified by associations with the other cancer
True discovery rate against the negative logarithm (base 10) of the p value for each cancer for subsets of genes based on strength of as-
sociation with the other cancer. The y axis of each plot is the true discovery rate, which is defined as 1  conditional FDR (cFDR). For a
given ordered analytic combination of datasets (e.g., GTEx normal breast tissue as transcriptome reference panel-breast cancer GWAS-
ovarian cancer GWAS, plotted in the upper left corner) we observed that, in general, for progressively smaller S-PrediXcan p values of the
second cancer type (indicated by the key ‘‘Threshold p’’ next to each plot), the true discovery rate (y axis) for associationwith the primary
cancer type approached 100% at progressively larger S-PrediXcan p values for the primary cancer type (x axis; negative logarithm [base
10] of the p values). Only p values > 106 are plotted on the x axis. BC, overall breast cancer risk; OC, all invasive ovarian cancer risk.Discussion
In this study, we used the conditional and conjunctional
FDR as a tool to systematically improve the power of breast
cancer and ovarian cancer candidate susceptibility gene
discovery in a PrediXcan-based TWAS. While gene expres-
sion predictionmodels based onmultiple tissue types have
been the more common approach to improving TWAS po-
wer,11,29 the conditional/conjunction FDR approach gains
power through the incorporation of multiple related
GWAS datasets into a TWAS analysis. We investigated the
shared inherited genetic basis of these two cancer types
by integrating normal and tumor-tissue-specific transcrip-
tomic datasets with large-scale genome-wide association
meta-analysis findings for susceptibility to breast cancer
and ovarian cancer. We identified 11 genomic regions asso-
ciated with breast cancer risk and five regions linked to
ovarian cancer risk.
We identified 14 candidate breast cancer susceptibility
genes (Table 1). Many of these genes have a strong biolog-
ical rationale for involvement in breast carcinogenesis and
are in or near genomic regions associated with other cancer6 Human Genetics and Genomics Advances 2, 100042, July 8, 2021types or potential cancer risk factors. For example, the
ZNF276 (MIM: 608460) intronic variant rs12925026 is
associated at genome-wide significance with non-mela-
noma skin cancer.30 ZNF276 overlaps FANCA (MIM:
607139) in a tail-to-tail manner.31 The genetically regu-
lated predictor model for ZNF276 expression was fit using
gene expression measured in GTEx breast tissues, but
neither this dataset nor any of the other datasets could cap-
ture a predictor model for FANCA expression. FANCA en-
codes one of eight subunits that together form the core
Fanconi Anemia (FA) complex that repairs blockages in
DNA replication due to cross-linking.32 Several members
of the FA family of proteins have been implicated in breast
and ovarian cancer predisposition, including BRCA1
(FANCS), BRCA2 (FANCD1), BRIP1 (MIM: 605882) (FANCJ),
PALB2 (MIM: 610355) (FANCN), RAD51C (MIM: 602774)
(FANCO), and FANCM (MIM: 609644), and it is possible
that FANCA may represent another or possibly the true
target breast cancer susceptibility gene in this region, given
this biological function and its overlap with ZNF276.32,33
ZNF276 in its own right has also been implicated as a
candidate tumor suppressor gene in breast cancer,31 and
Table 1. Candidate breast cancer susceptibility genes identified by pleiotropy-guided S-PrediXcan analysis
Gene Genomic region p value BC p value OC Conditional FDR BCjOC Conditional FDR OCjBC Conjunction FDR
Transcriptome reference panel: GTEx breast (normal)jprimary GWAS: overall BC risk (second GWAS: all invasive OC risk)
ZSCAN29 15q15.3 1.8E04 9.1E04 4.1E04 6.0E03 6.0E03
STRCP1 15q15.3 1.6E03 1.8E03 4.1E03 1.9E02 1.9E02
AC011330.5 15q15.3 5.4E04 2.5E03 1.8E03 2.2E02 2.2E02
STRC 15q15.3 1.4E04 3.8E03 6.1E04 2.2E02 2.2E02
ZNF276 16q24.3 3.7E06 4.7E03 2.4E05 2.2E02 2.2E02
RGS19 20q13.33 1.1E03 5.4E03 4.3E03 4.3E02 4.3E02
RNFT1 17q23.1 2.4E04 8.7E03 1.3E03 4.7E02 4.7E02
C15orf65 15q21.3 2.2E03 5.9E03 8.2E03 4.7E02 4.7E02
Transcriptome reference panel: TCGA breast (tumor)jprimary GWAS: overall BC risk (second GWAS: all invasive OC risk)
GMNC 3q28 2.6E03 1.2E03 6.1E03 2.0E02 2.0E02
ESRP2 16q22.1 1.9E02 9.6E04 4.3E02 3.3E02 4.3E02
BHLHA15 7q21.3 8.5E05 7.0E03 5.5E04 4.9E02 4.9E02
SCGB1D2 11q12.3 3.5E04 5.5E03 2.0E03 4.9E02 4.9E02
Transcriptome reference panel: TCGA breast (tumor)jprimary GWAS: ER-negative BC risk (second GWAS: HGSOC risk)
ETAA1 2p14 3.0E03 1.5E03 2.0E02 2.0E02 2.0E02
ATP8B4 15q21.2 1.6E03 2.2E03 1.5E02 2.4E02 2.4E02
Abbreviations: BC, breast cancer; OC, ovarian cancer; FDR, false discovery rate; ER, estrogen receptor; HGSOC, high-grade serous ovarian cancer.consistent with this potential tumor suppressor function
we observed that lower ZNF276 expression was associated
with increased breast cancer risk.
Other candidate breast cancer susceptibility genes we
identified include ESRP2 (MIM: 612960), which encodes
an epithelial cell-specific regulator of splicing of the breast
cancer susceptibility gene FGFR2 (MIM: 176943)34,35 and
SCGB1D2 (MIM: 615061), which encodes lipophilin B,
which is known to be expressed in both breast and ovarian
tumors.36 Lipophilin B is tightly co-expressed with and
forms a covalent complex with Mammaglobin A encoded
by SCGB2A2, the gene next to SCGB1D2.36 Mammaglobin
A may be used to detect disseminated or circulating tumor
cells and is under investigation as a potential immunother-
apeutic target in breast cancer.37 However, we were unable
to develop gene expression prediction models for
SCGB2A2 in breast normal or tumor tissues. BHLHA15
(MIM: 608606) encodes an estrogen-regulated transcrip-
tion factor that is required to maintain mammary gland
differentiation in mice,38 and we found that decreased
BHLHA15 expression was associated with greater suscepti-
bility to breast cancer. ETAA1 (MIM: 613196) harbors lead
variants associated at genome-wide significance with
pancreatic cancer39 and the hormone-related traits of age
at menopause40 and male-pattern baldness.41 It encodes
an activator of ATR kinase that accumulates at DNA dam-
age sites and promotes replication fork progression and
integrity.42 Breast cancer is closely linked to DNA damage
repair defects, and, in the presence of DNA damage, further
loss of ETAA1 has been shown to be synthetically lethal forH
the cell, suggesting that ETAA1 expressionmay be essential
for tumorigenesis on a background of DNA damage.43 In
keeping with this observation, we noted that elevated
ETAA1 expression was associated with increased breast
cancer risk. While our pleiotropy-guided transcriptome
imputation study was ongoing, a genome-wide association
meta-analysis for breast cancer risk that was performed in
parallel identified lead variants rs79518236 (184 kb from
BHLHA15) and rs9712235 (244 kb from ETAA1) at
genome-wide significance only on addition of 10,407
breast cancer cases and 7,815 controls to the Michailidou
et al.44 dataset used here. There were no known GWAS as-
sociations for breast cancer risk in these regions until the
larger GWAS meta-analysis, and our concomitant identifi-
cation of the same regions using gene expression imputa-
tion into a smaller GWAS underscores the power of
leveraging expression data to bolster genetic discovery.
We identified 11 candidate ovarian cancer susceptibility
genes (Table 2). As with breast cancer, there is strong sup-
port for a role of several genes in ovarian cancer pathogen-
esis, and many of these genes are in regions of the genome
that harbor pleiotropic associations with other cancer
types. Variants immediately upstream of CCNE1 (MIM:
123837) are associated at genome-wide significance with
bladder cancer risk.45 CCNE1 amplification is believed to
be an early event in the development of ovarian cancer46
and is a frequent somatic event in HGSOCs that do not
carry homologous recombination DNA repair pathway de-
fects.47 CCNE1 amplification is also associated with poor
prognosis in triple-negative breast tumors,48 and it isuman Genetics and Genomics Advances 2, 100042, July 8, 2021 7
Table 2. Candidate ovarian cancer susceptibility genes identified by pleiotropy-guided S-PrediXcan analysis.
Gene Genomic region p value OC p value BC Conditional FDR OCjBC Conditional FDR BCjOC Conjunction FDR
Transcriptome reference panel: GTEx ovary (normal)jprimary GWAS: all invasive OC risk (second GWAS: overall BC risk)
STRCP1 15q15.3 7.2E04 6.4E05 3.1E03 8.5E05 3.1E03
CPNE1 20q11.22 1.2E03 7.2E05 5.0E03 9.9E05 5.0E03
AC011330.5 15q15.3 1.7E03 2.6E05 5.8E03 4.5E05 5.8E03
CCNE1 19q12 1.9E03 3.2E03 1.4E02 4.4E03 1.4E02
CATSPER2P1 15q15.3 4.8E03 1.9E04 1.8E02 4.1E04 1.8E02
UQCC1 20q11.22 3.8E03 2.5E03 2.8E02 4.7E03 2.8E02
Transcriptome reference panel: TCGA ovary (tumor)jprimary GWAS: all invasive OC risk (second GWAS: overall BC risk)
CPNE1 20q11.22 2.0E03 9.0E05 2.0E02 4.9E04 2.0E02
Transcriptome reference panel: GTEx ovary (normal)jprimary GWAS: HGSOC risk (second GWAS: ER-negative BC risk)
CCNE1 19q12 1.7E03 2.0E04 5.9E03 1.5E03 5.9E03
STRCP1 15q15.3 9.2E03 3.2E04 3.1E02 3.9E03 3.1E02
HEATR3 16q12.1 4.3E03 3.1E02 4.6E02 4.4E02 4.6E02
Transcriptome reference panel: TCGA ovary (tumor)jprimary GWAS: HGSOC risk (second GWAS: ER-negative BC risk)
THSD7A 7p21.3 1.5E03 1.2E02 2.8E02 4.3E02 4.3E02
Abbreviations: BC, breast cancer; OC, ovarian cancer; FDR, false discovery rate; ER, estrogen receptor.worth noting that we observed the stronger conjunction
FDR association signal for CCNE1 in the pleiotropy-
informed analysis that was based on the HGSOC and ER-
negative breast cancer susceptibility GWAS datasets (Table
2). However, we noted that increased CCNE1 expression
was associated with decreased HGSOC (and ER-negative
breast cancer) risk. This paradoxical direction of risk effect
may be explained by the fact that CCNE1 amplification is
less common and the loss of homologous recombination
(HR) pathway function is far more common in ovarian
cancer, and, in the absence of a functional HR pathway,
CCNE1 is known to be essential for the developing tumor
cell to survive.49 This study suggests a role for CCNE1 in
conferring ovarian cancer risk. Intronic variants inHEATR3
(MIM: 614951) are associated at genome-wide significance
with glioma in European ancestry individuals50 and with
squamous cell esophageal carcinoma in East Asian ancestry
individuals.51 HEATR3was also identified by a TWAS of gli-
oma susceptibility.52 Intronic variants in THSD7A (MIM:
612249) are associated with epithelial ovarian cancer risk
in East Asians,53 albeit not at genome-wide significance
(lead variant rs10260419 p ¼ 1 3 107). Gene expression
prediction models derived from breast and ovarian tissues
both implicated the 15q15.3 region as a breast and ovarian
cancer susceptibility region on imputation with these
models into the breast and ovarian cancer GWAS data.
Our analysis suggested several genes in this region (Tables
1 and 2), with the pseudogene STRCP1 as the only com-
mon gene across breast and ovarian tissues. STRCP1 over-
laps the protein coding gene STRC (MIM: 606440), also
identified in the breast-tissue-based analysis (Table 1),
and variants in STRC have previously been associated8 Human Genetics and Genomics Advances 2, 100042, July 8, 2021with lung cancer risk (lung cancer lead variant
rs35028925 p ¼ 2 3 106).54
In this analysis, we chose to label the identified genes as
candidate breast cancer susceptibility genes if they were
identified on integrating the GTEx or TCGA breast expres-
sion prediction models with the breast cancer GWASs and
incorporating pleiotropic information from the ovarian
cancer GWASs and vice versa for candidate ovarian cancer
susceptibility genes. However, application of the conjunc-
tion FDR over and above the conditional FDR in principle
identified genes associated with both cancer types by tap-
ping into GWAS data from both cancers. Therefore, in a
sense, all these genes may well be regarded as candidate
breast and ovarian cancer susceptibility genes. Moreover,
in our pleiotropy-guided study design, the ovarian cancer
dataset, in a sense, served as a replication dataset for the
breast cancer findings and vice versa, which was particu-
larly important given the lack of adequately powered and
truly independent breast and ovarian cancer datasets
outside of the datasets used in this study.55
We identified 38 candidate breast cancer susceptibility
genes and 17 candidate ovarian cancer susceptibility genes
in regionspreviously implicatedbyGWASs for breast cancer
and ovarian cancer, respectively (Tables S3 and S5). The
identification of a large number of genes in these regions
is unsurprising, given that GWAS associations are the key
determinant of the S-PrediXcan signal. However, we were
able to take advantage of fine-scalemapping data generated
by the Breast and Ovarian Cancer Association Consortia to
separatelypinpoint thosegeneswhereafine-mappedcandi-
date causal GWAS risk variant was incorporated in the Pre-
diXcan model, suggesting that it drives the gene-based
association. Overall, we found this to be the case for 60% of
the candidate susceptibility genes identified by PrediXcan
in the breast and ovarian cancer susceptibility regions iden-
tified by GWASs. Comprehensive functional follow-up of
the 19p13.11 breast and ovarian cancer GWAS region sug-
gests that ABHD8 and ANKLE1 are the most likely targets
in this region.5 While there was no overlap between S-Pre-
diXcan model variants for ABHD8 and ANKLE1 and fine-
mapped risk variants in this region, S-PrediXcan did detect
both genes as candidate causal susceptibility genes, with
ANKLE1 being the only gene that made the cut in both
breast and ovarian tissues, suggesting that S-PrediXcan
applied to pleiotropic gene-dense regions such as
19p13.11 does help short-list the key targets even in the
absence of overlap with fine-mapped variants. A total of
21/38 breast and 13/17 ovarian cancer candidate suscepti-
bility genes in the published GWAS regions were clustered
at 17q21.31, reflecting the unique long-distance linkage
disequilibriumstructure of this region.56 This phenomenon
has also led to clustering of associations at 17q21.31 in pre-
vious TWASs of breast or ovarian cancer risk.9,11
Gene expression prediction models in this study were
built using genomic data from women with genetically
inferred European ancestry. The predictive performance
of these models in a non-European ancestry cohort
was not evaluated. Thus, a key limitation of this study
is the potential lack of generalizability of these models
to non-European ancestry cohorts. Recent analyses
suggest that default TWAS models trained in large
datasets such as GTEx suffer from a significant reduction
in prediction accuracy, particularly in individuals of Afri-
can ancestry, when compared to those of European
ancestry.57 There is an urgent and compelling need for
trans-ancestry datasets that drive TWAS in diverse ances-
tral cohorts.
In conclusion, the powerful combination of pleiotropic
breast and ovarian cancer GWAS datasets with transcrip-
tome imputation from normal and tumor breast and
ovarian tissues identified a total of 16 genomic loci (22
genes) associated with breast and ovarian cancer risks.
Fine-mapping in larger GWAS datasets and deeper labora-
tory-based functional follow-up studies of these loci and
candidate genes have the potential to provide fresh in-
sights into the common biological underpinnings of breast
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Figure S1: Prediction performance of PrediXcan models in normal and tumor breast and ovarian tissues. 
 
Pred_perf_r2 is the cross-validated R2 of the tissue model's correlation to the gene's measured transcriptome 
(prediction performance).  This prediction performance is displayed for the GTEx normal breast and ovarian 
tissues and the TCGA breast and ovarian tumor tissues, demonstrating that, in general, prediction performance 
was better for the GTEx normal tissues than the TCGA tumor tissues. 
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Figure S2: True discovery rate of S-PrediXcan associations for each cancer stratified by associations with the other cancer 
for the subtype-specific analyses. 
 
True discovery rate against the negative logarithm (base 10) of the P-value for each cancer for subsets of genes 
based on strength of association with the other cancer for the subtype-specific analyses.  The Y-axis of each plot 
is the true discovery rate which is defined as 1 – conditional false discovery rate (cFDR).  For a given ordered 
analytic combination of data sets (e.g., GTEx normal breast tissue as transcriptome reference panel-estrogen 
receptor (ER)-negative breast cancer GWAS-high-grade serous ovarian cancer (HGSOC) GWAS, plotted in the 
upper left hand corner) we observed that, in general, for progressively smaller S-PrediXcan P-values of the 
second cancer type (indicated by the key “Threshold p” next to each plot), the true discovery rate (Y-axis) for 
association with the primary cancer type approached 100% at progressively larger S-PrediXcan P-values for the 
primary cancer type (X-axis; negative logarithm (base 10) of the P-values).  BC: ER-negative breast cancer risk; 
OC: HGSOC risk.  Only P-values > 10-6 are plotted on the X-axis. 
 
